Compensation to clinical trial participants in India: A gap analysis
1★, 1, 1, 1★ Corresponding author
- 1Department of Pharmacology, Central Research Institute of Unani Medicine, Under CCRUM, Ministry of AYUSH Government of India, Hyderabad, Telangana, INDIA.
CORRESPONDENCE
Mohd Urooj
Department of Pharmacology, Central Research Institute of Unani Medicine, Under CCRUM, Ministry of AYUSH Government of India, Hyderabad, Telangana, INDIA.
Volume 7, Issue 2 · pp. 41-46 · 2017 · DOI: 10.4103/jphi.JPHI_31_17
ABSTRACT
The recent amendments notified by the Government of India, for conducting clinical trial, is greatly appreciable as promoting safety and well‑being of human subjects. These rules clearly state that medical management of injuries in clinical trials is mandatory, and clinical trial‑related injury or death needs to be compensated over and above the medical management. These rules need to be reconsidered for simplification and better understanding of issues regarding compensation. There is a need of clarity at some points which should be discussed with all stakeholders for better understanding of current regulations. In our view, attention must also be given to academic investigators, during discussion to promote availability of cost‑effective treatment in India.
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Urooj, M., Husain, G. M., Khan, M. A., & Kazmi, M. H. (2017). Compensation to clinical trial participants in India: A gap analysis. International Journal of Pharmaceutical Investigation, 7(2), 41-46. https://doi.org/10.4103/jphi.JPHI_31_17
Copyright and licence
© 2017 Author(s)
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. CC BY-NC-SA 4.0